| Disclosure of detailed information about intangible assets [Table Text Block] |
| |
|
Cultivations and processing licenses (*)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 1, 2024
|
|
$
|
2,524
|
|
|
$
|
12,727
|
|
|
$
|
1,564
|
|
|
$
|
10,095
|
|
|
$
|
23
|
|
|
$
|
26,933
|
|
|
Impairment
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(495
|
)
|
|
|
-
|
|
|
|
(495
|
)
|
|
Deconsolidation of Oranim
|
|
|
-
|
|
|
|
(2,822
|
)
|
|
|
-
|
|
|
|
(3,499
|
)
|
|
|
-
|
|
|
|
(6,321
|
)
|
|
Foreign currency translation adjustments
|
|
|
147
|
|
|
|
174
|
|
|
|
-
|
|
|
|
578
|
|
|
|
-
|
|
|
|
899
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2024
|
|
|
2,671
|
|
|
|
10,079
|
|
|
|
1,564
|
|
|
|
6,679
|
|
|
|
23
|
|
|
|
21,016
|
|
|
Impairment
|
|
|
(997
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(5,390
|
)
|
|
|
-
|
|
|
|
(6,387
|
)
|
|
Foreign currency translation adjustments
|
|
|
123
|
|
|
|
101
|
|
|
|
-
|
|
|
|
596
|
|
|
|
-
|
|
|
|
820
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2025
|
|
|
1,797
|
|
|
|
10,180
|
|
|
|
1,564
|
|
|
|
1,885
|
|
|
|
23
|
|
|
|
15,449
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 1, 2024
|
|
|
1,691
|
|
|
|
7,798
|
|
|
|
1,523
|
|
|
|
-
|
|
|
|
23
|
|
|
|
11,035
|
|
|
Amortization during the year
|
|
|
-
|
|
|
|
1,369
|
|
|
|
8
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,377
|
|
|
Deconsolidation of Oranim
|
|
|
-
|
|
|
|
(1,408
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,408
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2024
|
|
|
1,691
|
|
|
|
7,759
|
|
|
|
1,531
|
|
|
|
-
|
|
|
|
23
|
|
|
|
11,004
|
|
|
Amortization during the year
|
|
|
-
|
|
|
|
1,330
|
|
|
|
8
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,338
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2025
|
|
|
1,691
|
|
|
|
9,089
|
|
|
|
1,539
|
|
|
|
-
|
|
|
|
23
|
|
|
|
12,342
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized cost at December 31, 2025
|
|
$
|
106
|
|
|
$
|
1,091
|
|
|
$
|
25
|
|
|
$
|
1,885
|
|
|
$
|
-
|
|
|
$
|
3,107
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized cost at December 31, 2024
|
|
$
|
980
|
|
|
$
|
2,320
|
|
|
$
|
33
|
|
|
$
|
6,679
|
|
|
$
|
-
|
|
|
$
|
10,012
|
|
| |
(*) |
The licenses consisted of GMP and GDP licenses in Germany that had indefinitely useful life. The Company recognized an impairment loss in total amount of $997 during the year ended December 31, 2025 (see below).
|
|